Skip to content
TrialScanner

NCT03170960

Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors

Phase 1Active, not recruitingEXELLead

Registry record

Lead sponsor
Exelixis
Conditions
Urothelial Carcinoma; Renal Cell Carcinoma; Non-Small Cell Lung Cancer; Castration-resistant Prostate Cancer; Triple Negative Breast Cancer
Primary completion
Feb 21, 2023Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT03170960 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.